Search

Displaying results 481 - 490 of 4300 in total
  1. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. … barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved

  2. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.

  3. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Patients often experience persistent or exacerbating symptoms overtime despite conventional first-line therapies available. … In four double-blind, randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to

  4. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Due to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.

  5. Drug

    Tannic acid

    go.drugbank.com/drugs/DB09372
    ApprovedInvestigational

    It is a type of the commercially available tannins. It acts as a weak acid. … Tannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer.

  6. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. … In December 2019, Ervebo was approved by the FDA in the United States.

  7. Drug

    Coal tar

    go.drugbank.com/drugs/DB11082
    Approved

    Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. … It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.

  8. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  9. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but

  10. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.